With $36.7B In Cash, Bank of America Expects Gilead To Shop For Complements To Drug Pipeline

By: via Benzinga
Gilead Sciences, Inc. (NASDAQ: GILD) announced fourth-quarter results Tuesday that revealed better-than-expected top- and bottom-line ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.